Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted triglyceride-lowering strategy in aortoiliac occlusive disease
ChiCTR2600131252Phase 4Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fenofibrate and ulinastatin in aortoiliac occlusive disease (AIOD) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Incidence of Major Adverse Limb Events (MALE). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
fenofibrateulinastatin
03
Conditions
aortoiliac occlusive disease (AIOD)
Beyond the preview
Go deeper on ChiCTR2600131252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131252.